ArticleScientific reports2025
Hepatoprotective potential of M3F, a benzimidazole pyrazole derivative, against paracetamol induced hepatotoxicity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatotoxicity, a critical liver damage often caused by drugs like paracetamol (PCM), involves oxidative stress, inflammation, and cellular injury. This study investigates the hepatoprotective potential of a benzimidazole-pyrazole derivative, 2-((1H-benzo[d]imidazol-2-yl) thio)-1-(3-(2-fluorophenyl)-5-phenyl-1H-pyrazol-1-yl) ethanone (M3F), using both in silico and in vivo approaches. Pharmacokinetic profiling was performed using SwissADME and ProTox to predict drug-likeness and toxicity. Molecular docking studies were conducted using AutoDock Vina integrated with PyRx to evaluate the binding affinity of M3F with key targets related to oxidative stress and inflammation. Subsequently, in vivo studies were conducted using a PCM-induced hepatotoxicity model in mice, wherein M3F was administered orally at doses of 100, 200, and 400 µg/kg for seven consecutive days, followed by a single dose of PCM (300 mg/kg, intraperitoneally) on the eighth day to induce liver injury. Serum markers of liver damage, lipid profiling, antioxidant assays, histopathological examinations and molecular markers analysis were performed to determine the therapeutic effects of M3F. In silico analysis revealed favorable pharmacokinetic properties and strong binding affinities of M3F to inflammatory and oxidative stress-related molecular targets. In vivo, M3F treatment led to a marked improvement in liver enzyme levels and lipid profiles, along with significant histological recovery of liver tissue. The study demonstrated a significant downregulation of IL-6, IL-1β, and TNF-α protein levels, as measured by ELISA, indicating reduced inflammatory responses following M3F treatment. Additionally, PCR analysis revealed a notable decrease in the mRNA expression levels of IL-17, NF-κB, and TLR4, alongside an increase in Nrf2 and HO-1 transcript levels. It is suggested that M3F demonstrated notable hepatoprotective effects in PCM-induced liver injury through dual modulation of inflammatory (NF-κB) and antioxidant (Nrf2) pathways. These findings support its potential as a novel hepatoprotective candidate for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.